Cytacoat is a private Swedish company located in the Karolinska Institutet Science Park in Solna, Stockholm. Founded by a group of researchers from the prestigious Karolinska Institute and the Royal Institute of Technology, Cytacoat aims to develop a groundbreaking antibacterial coating for medical devices. Their proprietary polymer surface has shown promising results against several problematic pathogenic bacteria commonly found in healthcare settings.

With a fully equipped laboratory in the Karolinska Institutet Science Park, Cytacoat conducts microbiology evaluations, optimizes their technology, and even has a pilot plant for production. They have established collaborations with clinical experts at Karolinska University Hospital Neonatal Unit and the Division of Clinical Microbiology. Additionally, Cytacoat works closely with regulatory consultants, experienced clinical research organizations, patent experts, and specialist analysis providers.

Led by CEO Graeme Brookes, an accomplished leader in the medical device industry, Cytacoat is dedicated to transforming their innovative technology into a commercial product and making it available through licensing agreements. Explore more about Cytacoat and their revolutionary antimicrobial coating on their website